🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Surgery Partners, Inc. SGRY R2K

Healthcare · Medical Care Facilities · United States
https://www.surgerypartners.com
Company Profile ↓
$15.12
-32.71% 1Y
Mkt Cap$1.98B
P/E-25.63
P/B1.18
52W High$23.84
52W Low$11.49
Book Value$13.03
EPS (TTM)$-0.59

Company Overview

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 25.0% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $3.31B (+6.2% YoY); net profit $-77.90M.
  • Trailing 12 Months Year-on-year growth — revenue +4.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 25.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:24.98%
1 Year:4.50%

Stock Price Performance

1 Year:-32.71%
6 Months:-6.20%
3 Months:+15.51%
1 Month:+1.20%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 29% of range
$11.49 $23.84
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)45.28 · Neutral
Price Performance
1M+1.20%
3M+15.51%
6M-6.20%
1Y-32.71%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 25.0% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 36.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-25.63
Industry PE
25.41
Forward P/E
23.11
PEG Ratio
-
Book Value
$13.03
Price to Book
1.18
P/S
0.60
EV/EBITDA
11.70
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
24.98%
Profit 5Y
-
Revenue (YoY)
4.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
5.19%
ROE
2.75%
ROA
3.70%
Profit Margin
-2.28%
Op Margin
10.37%
Gross Margin
22.83%
EPS (Latest Qtr)
$-0.28
EPS (TTM)
$-0.59

Balance Sheet & Liquidity

Debt/Equity
1.16
Quick Ratio
1.35
Current Ratio
1.86
Debt
$4.04B
Total Assets
$8.04B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.76%
Chg in Prom Hold
0.04%
FII / Inst Holding
123.26%
Chg in FII Hold
-0.07%

Financial Snapshot

Enterprise Value
$1.98B
Total Revenue (TTM)
$3.34B
EBITDA
$652.20M
Free Cash Flow
$199.06M
Operating Cash Flow
$280.00M
Shares Outstanding
130.79M
Gross Margin
22.83%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SGRY Surgery Partners, Inc. R2K 15.12 -25.63 $1.98B 0.00% 5.19% 2.75% 24.98% -
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue 76.30M179.69M224.14M232.83M239.60M263.32M267.07M289.68M282.68M306.00M286.18M288.35M460.35M417.37M--------------------------
Operating Income 19.65M-38.35M41.00M44.27M-34.28M50.95M42.85M-41.72M37.74M-41.20M43.50M45.00M-49.60M55.50M59.00M-23.50M44.70M18.50M64.30M59.50M63.60M100.40M76.50M74.10M46.40M97.60M82.60M76.00M84.80M60.90M61.90M111.70M105.70M65.80M
Net Income -6.91M-54.26M-6.76M-5.43M-3.12M16.74M-7.19M2.12M-2.34M16.86M-2.75M-4.47M-32.18M-17.50M-19.50M-21.00M-147.70M-20.10M-19.80M-15.70M-19.20M-27.50M-32.50M-61.60M-21.00M-26.90M-22.90M12.20M-18.40M-25.00M-24.90M18.90M-4.90M-12.40M-15.50M-31.70M-37.70M-2.50M-22.70M-35.90M
Diluted EPS -0.22-1.69-0.21-0.17-0.100.35-0.150.04-0.050.35-0.06-0.09-0.83-0.53-0.57-0.61-3.25-0.60-0.59-0.51-0.59-0.76-0.86-1.46-0.57-0.39-0.280.14-0.21-0.28-0.200.15-0.04-0.10-0.12-0.25-0.30-0.02-0.18-0.28

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 284.60M403.29M959.89M1.15B1.77B1.83B1.86B2.23B2.54B2.74B3.11B3.31B
Operating Income 58.23M50.81M144.75M196.48M77.80M235.90M183.00M302.20M345.20M328.00M348.80M389.50M
Net Income -9.06M-65.90M1.43M9.45M-205.70M-74.80M-116.10M-70.90M-54.60M-11.90M-168.10M-77.90M
Diluted EPS -0.28-2.040.040.20-4.96-2.29-3.19-1.12-0.59-0.09-1.33-0.61

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Aug 2017Sep 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.86B2.10B2.30B--4.62B4.68B5.02B5.41B6.12B6.68B6.88B7.89B8.12B
Total Equity 124.11M-14.38M-264.08M-4.03M9.68M480.00M1.41B654.73M404.60M296.80M115.60M1.09B2.00B1.99B1.79B1.71B
Cash & Equivalents 5.23M13.03M74.92M57.93M69.70M214.21M-174.91M184.30M92.70M317.90M389.90M282.90M195.90M269.50M239.90M
Long Term Debt ---1.29B1.47B--2.19B2.33B2.60B2.88B2.96B2.63B2.80B3.40B3.74B
Current Liabilities --141.39M181.29M186.72M--303.00M349.30M398.10M556.80M536.80M493.40M523.00M624.40M615.50M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 49.08M21.95M84.48M125.24M144.60M129.50M246.90M87.10M158.80M293.80M300.10M274.30M
Investing Cash Flow -3.62M-271.02M-134.84M-184.75M-128.90M-85.20M-88.40M-331.70M-307.90M-225.60M-488.50M-246.60M
Financing Cash Flow -37.66M310.96M33.37M71.28M-6.30M-135.90M66.70M316.30M42.10M-155.20M262.00M-57.30M
Capital Expenditure -4.15M-7.74M-33.44M-39.11M-39.80M-73.60M-42.90M-57.60M-80.60M-88.80M-90.40M-78.70M
Free Cash Flow 44.93M14.21M51.04M86.13M104.80M55.90M204.00M29.50M78.20M205.00M209.70M195.60M
Share Buybacks 03.14M002.00M00-----

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------
Operating Margin % 20.5%12.6%15.1%17.2%4.4%12.9%9.8%13.6%13.6%12.0%11.2%11.8%
Net Margin % -3.2%-16.3%0.1%0.8%-11.6%-4.1%-6.2%-3.2%-2.2%-0.4%-5.4%-2.4%
ROE % 63.0%25.0%-35.5%97.7%-50.8%-25.2%-100.4%-6.5%-2.7%-0.6%-9.4%-4.5%
ROCE % -3.0%7.5%9.3%1.8%5.1%3.8%5.4%5.6%5.2%4.8%5.2%

Shareholding Pattern

Insiders
1.76%
Institutions
123.26%
Public Float
125.47%

Top Institutional Holders

#Holder% HeldSharesValue
1 Bain Capital Investors Llc 38.19% 49.95M $858.09M
2 Janus Henderson Group PLC 10.35% 13.54M $232.62M
3 Pentwater Capital Management Lp 9.68% 12.65M $217.41M
4 King Street Capital Management, LP 7.82% 10.23M $175.75M
5 UBS Group AG 7.79% 10.19M $175.09M
6 Blackrock Inc. 4.33% 5.66M $97.25M
7 Dimensional Fund Advisors LP 4.05% 5.30M $90.99M
8 ClearBridge Investments, LLC 3.15% 4.12M $70.75M
9 Vanguard Portfolio Management LLC 2.77% 3.63M $62.34M
10 Vanguard Capital Management LLC 2.62% 3.43M $58.94M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SGRY

Google News ue, 14 Jul 2026

Surgery Partners (SGRY) director receives 34,364 restricted stock awards - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNeW1JOWtxYmpxcjVFSXExS0l4eGl4QWlMd3FVcFBRQWphdkFlUHdoZ1luZVJLUXhOVmxwZ0Zvc0JSTzhsV2g1NWtwVEJtenk2ZlA1Sl9md1FLZWNTOE10MTV3YVJMRVhxUEg1TTJHcVVnellwTEhLSl9zaXhJUUpLUHhJM1VhLU5yN0I1Mm…

Google News Sat, 11 Jul 2026

Surgery Partners (SGRY) Could Be 9% Undervalued As Outpatient Surgery Growth Narrative Builds - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNMl8wUFMtSndlal9oXzdOcVRSajNEZ2lMQWNNeTN5Sno1T29scFJRenN4Vmt1dVdNNXNJd1Y1dEJONnhTc1JUaFZiWFVKa1NVcWVab29EWUlvdDRicFhKLXVVZ2RpNEVZdjh5d0g3OEtldUJDUW5JZkNvT21JOERnVDF4NU1zVjhIUjczUn…

Google News hu, 02 Jul 2026

Why Surgery Partners (SGRY) Stock Is Trading Up Today - TradingView

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNeGM1azhoaDRablRkOTN1TEhEbWRQcERxaEpYOHV1WWNHeWJTTFJUM01RbGVNODV2d0RZYXZTMFMwWVh6RU1VTks1aVRKSXhubi1OWkJiSEZreUdfaXM2OFpIM0d0TE12ZlhsMmgwTXJpTnBCZzRuWlZueG9BajViZl9YT1BVZ25UNlMwbj…

Google News Mon, 13 Jul 2026

Is Surgery Partners (SGRY) Reframing Its Profit Engine With Higher-Acuity Outpatient Surgeries? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPLTYzc2tZLU03aWxzTlFUY05DajFFYXJmY2REUHRRVXZrVmVBWkctNS02cjdURkRDMU5SNVhjYjQybzlOWkloQ3VPUWRaMENQWnFubVcxb0dJWU14R0QxZnc0X0pudUQxLThYQXBfdDFTQlp4M08xc21EWHNGcnNUaWZBVFkxbnRlbnZDX1…

Google News hu, 23 Apr 2026

1 Mooning Stock with Impressive Fundamentals and 2 We Ignore - StockStory

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPdE1DTjF2T0lVLXVHQ2V2MkFxdENQT3ZXMGltblVEZXZlZ25kU2V1bi1rR092NGp4VVE3cUhnNGc1TTJZbWRseWZDMllvSU9iZDM2aUlOeUxfU1BBZm5KWVJrQmVBTEtNemxTTUhiXy1KbkNsRzdLT2tqV3lwWFdmclJqYkpMcFZNVUltQW…

Google News hu, 09 Jul 2026

Avoiding Lag: Real-Time Signals in (SGRY) Movement - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNZmUwcUtwN2dhNG9oOHZhTTdPaG9BU2hDU0hMRWZyTmFiUWRRaHA0MXpRXzNpNHhxWi1tVzdMeDBqVjlkNGdBek91US1DRXlqdjFSeGhiN01Yc3lMN1JPaU5VMzNWY1R5N0piclJxRmtGQ0JWSUU0eTlNNGVPVkdwN2JTRThpdUJtN0RrRl…

SGRY — Frequently Asked Questions

What is the current share price of Surgery Partners, Inc. (SGRY)?

As of 2026-07-14 21:23 PDT, Surgery Partners, Inc. (SGRY) trades at $15.12 on NasdaqGS. Its 52-week range is $11.49 to $23.84.

What is the market capitalisation of SGRY?

Surgery Partners, Inc. (SGRY) has a market capitalisation of $1.98B on NasdaqGS.

What is the P/E ratio of SGRY?

SGRY trades at a trailing price-to-earnings (P/E) ratio of -25.63. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.18.

What is the return on equity (ROE) of SGRY?

SGRY has a return on equity (ROE) of 2.75%. Its return on capital employed (ROCE) is 5.19%.

Is SGRY a good stock to buy?

This page provides a data-driven analysis of Surgery Partners, Inc. (SGRY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space